Table 2 Results of the univariate and multivariable regression analysis of tigecycline-induced hypofibrinogenemia

Age

1.03 (1.01 ∼ 1.04)

< 0.001

1.02 (1.01 ∼ 1.04)

0.009

Male

1.52 (0.98 ∼ 2.34)

0.061

Duration

1.28 (1.22 ∼ 1.36)

< 0.001

1.33 (1.25 ∼ 1.41)

< 0.001

Therapeutic regimen

1.46 (0.94 ∼ 2.27)

0.090

ALT

1.00 (1.00 ∼ 1.00)

0.386

AST

1.00 (1.00 ∼ 1.00)

0.213

TBIL

1.01 (1.00 ∼ 1.02)

0.134

CREA

1.00 (1.00 ∼ 1.00)

0.643

APTT

1.02 (1.01 ∼ 1.04)

0.039

1.02 (1.00 ∼ 1.05)

0.060

PT

0.99 (0.96 ∼ 1.03)

0.690

Baseline Fibrinogen

0.66 (0.56 ∼ 0.78)

< 0.001

0.65 (0.53 ∼ 0.80)

< 0.001

PLT×10⁹/L

0.99 (0.99 ∼ 0.99)

0.037

0.99 (0.99 ∼ 0.99)

0.025

WBC×10⁹/L

—

0.809

Concomitant disease

 COPD

1.16 (0.72 ∼ 1.84)

0.544

 Hypertension

0.92 (0.62 ∼ 1.37)

0.697

 Diabetes

1.14 (0.73 ∼ 1.79)

0.555

 Coronary heart disease

1.33 (0.90 ∼ 1.98)

0.153

 Tumour

1.82 (1.08 ∼ 3.06)

0.025

2.17 (1.12 ∼ 4.18)

0.021

 Autoimmune disease

1.16 (0.54 ∼ 2.49)

0.695

 Cerebrovascular disease

1.08 (0.73 ∼ 1.60)

0.714

Types of infection

 Pulmonary

1.01 (0.59 ∼ 1.71)

0.973

 Blood

0.69 (0.33 ∼ 1.41)

0.308

 Urinary tract

1.21 (0.77 ∼ 1.89)

0.413